苄基1-哌啶基氨基甲酸酯 | 126216-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄基1-哌啶基氨基甲酸酯
• 英文名称: benzyl N-piperidin-1-ylcarbamate
• CAS: 126216-46-4
• 化学式: C₁₃H₁₈N₂O₂
• mdl: MFCD00961875
• 分子量: 234.298
• InChiKey: RARCRVJUYCOHBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  benzyl N-[2,6-bis(benzotriazol-1-yl)piperidin-1-yl]carbamate 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到苄基1-哌啶基氨基甲酸酯
  参考文献：
  名称：

  The chemistry of benzotriazole. A novel and versatile synthesis of 1-alkyl-, 1-aryl-, 1-(alkylamino)-, or 1-amido-substituted and of 1,2,6-trisubstituted piperidines from glutaraldehyde and primary amines or monosubstituted hydrazines

  摘要：

  DOI：

  10.1021/jo00297a041

文献信息

• TREPROSTINIL PRODRUGS
  申请人：United Therapeutics Corporation

  公开号：US20210054009A1

  公开（公告）日：2021-02-25

  Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

  提供了特瑞普罗斯汀的新型前药，以及制备这些前药的方法和使用这些前药的方法。
• Inhibitors of cyclin-dependent kinase 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS, INC.

  公开号：US10106526B2

  公开（公告）日：2018-10-23

  The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式(I)和式(II)的新型化合物及其药学上可接受的盐、溶液剂、水合物、同系物、立体异构体、同位素标记的衍生物及其组合物。还提供了涉及这些化合物或组合物的方法和试剂盒，用于治疗或预防受试者的增殖性疾病（如癌症（如白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可抑制细胞周期蛋白依赖性激酶7（CDK7）的异常活性，从而诱导细胞凋亡和/或抑制受试者体内的转录。
• Amination with N-benzyloxycarbonyl-3-phenyloxaziridine as a route to sensitive chiral α-hydrazino acids: Synthesis of l-hydrazino serine
  作者：Daniel A. Niederer、James T. Kapron、John C. Vederas

  DOI：10.1016/s0040-4039(00)91814-8

  日期：1993.10

  N-Cbz-3-phenyloxaziridine can be generated in a two step process. This is a new reagent for direct electrophilic N-amination of chiral alpha-amino acids and their derivatives which affords the corresponding hydrazino acids protected with a readily removable N-Cbz group. Application of this methodology to a facile synthesis of L-hydrazino serine, a potentially useful biological tool, is described
• KATRITZKY, ALAN R.;FAN, WEI-QIANG, J. ORG. CHEM., 55,(1990) N0, C. 3205-3209
  作者：KATRITZKY, ALAN R.、FAN, WEI-QIANG

  DOI：——

  日期：——
• SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Merck & Co., Inc.

  公开号：EP2091328A2

  公开（公告）日：2009-08-26